Call for proposals - FP7 HEALTH 2010 - Collaborative projects (single-stage submission) HEALTH Closed!


Improving the health of European citizens and increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics. Emphasis will be put on translational research (translation of basic discoveries in clinical applications including scientific validation of experimental results), the development and validation of new therapies, methods for health promotion and prevention including promotion of child health, healthy ageing, diagnostic tools and medical technologies, as well as sustainable and efficient healthcare systems.

A targeted action is launched for the development of safety methods with higher predicted value, faster and cheaper than animal tests.

Providing tools for translational research: Developing tools for translational research is an overarching objective of the Health Theme, which includes the following aspects: Systems biology, cell therapy and diagnostics. Overall this will contribute towards structuring EU efforts and better understanding of disease mechanisms, drug discovery and translational research.

Structuring translational research in the field of cancer: The aim is to develop a structured European approach in both the areas of cancer systems biology and cancer therapy by bringing together resources not available in any single country. The former will facilitate understanding the complex networks of genes involved in cancer development. The latter addresses comprehensively new avenues for cure. Other areas of action include survivor studies as well as patient stratification technologies.

Structuring translational research in the field of neurodegenerative diseases: Neurodegenerative diseases and particularly dementia are becoming a global medical and socio-economic challenge. Only a structured European approach can address this major  challenge by pooling and coordinating the efforts of basic and clinical researchers in this field.

In adition to our useful documents section, further information about Call FP7 Health 2010, as well as relevant documents can be found at the Cordis website


Activities for the call FP7-Health 2010 and topics called:

1. Biotechnology, generic tools and medical technologies for human health

1.1 High throughput research

  • HEALTH.2010.1.1-1: Harmonisation of phenotyping and biosampling for human large-scale research biobanks.
  • HEALTH.2010.1.1-3: High-throughput analysis of post- translational modifications of proteins.

1.2 Detection, diagnosis and monitoring

  • HEALTH.2010.1.2-2: Stratification approaches and methodologies to select from a wide range of biomarkers relevant candidates for clinical validation.
  • HEALTH.2010.1.2-3: Harmonization, validation and standardisation in genetic testing.
  • HEALTH.2010.1.2-4: Early events in acute hepatitis C virus (HCV) infection with the aim to identify new biomarkers.

1.4 Innovative therapeutic approaches and interventions

  • HEALTH.2010.1.4-1: Translational research on cell-based immunotherapy.

2. Translating research for human health

2.1. Integrating biological data and processes: large-scale data gathering, systems biology

  • HEALTH.2010.2.1.1-1: Large-scale efforts in mouse functional genomics to determine the functions of genes and their involvement in disease.
  • HEALTH.2010.2.1.1-2: Coordination action(s) on standards in large scale data gathering.
  • HEALTH.2010.2.1.2-3: Developing new and improving existing mathematical algorithms for systems biology.

2.2. Research on the brain and related diseases, human development and ageing

  • HEALTH.2010.2.2.2-5: Frailty and its implications in modern society.

2.3. Translational research in major infectious diseases: to confront major threats to public health

  • HEALTH.2010.2.3.2-1: Target characterisation and hit-to-lead progression in tuberculosis (TB) drug development.
  • HEALTH.2010.2.3.2-2: Lead optimisation and late preclinical development in tuberculosis (TB) drugs
  • HEALTH.2010.2.3.2-3. European network of cohort studies on HIV/AIDS.
  • HEALTH.2010.2.3.3-1: Biology and control of vector-borne infections in Europe.
  • HEALTH.2010.2.3.3-2: Drug lead discovery against RNA viruses.
  • HEALTH.2010.2.3.3-3: Integrated disease-specific research on West Nile Virus infections, Chikungunya and/or Crimean Congo Haemorrhagic Fever.
  • HEALTH.2010.2.3.4-1: Vaccines for childhood bacterial diarrhoeal diseases.
  • HEALTH.2010.2.3.4-2: Comprehensive control of Neglected Infectious Diseases.
  • HEALTH.2010.2.3.4-3: Next generation of researchers for Neglected Infectious Diseases.

2.4. Translational research in other major diseases

  • HEALTH.2010.2.4.1-2: Structuring translational cancer research between cancer research centres in Europe.
  • HEALTH.2010.2.4.1-3: Structuring clinical research in paediatric and adolescent oncology in Europe.
  • HEALTH.2010.2.4.2-1: Reducing in-stent thrombosis.
  • HEALTH.2010.2.4.2-2: New approaches to reduce ischemic damage to the heart.
  • HEALTH.2010.2.4.2-4: Diastolic heart failure.
  • HEALTH.2010.2.4.4-1: Clinical development of substances with a clear potential as orphan drugs.
  • HEALTH.2010.2.4.5-1: Investigation of the mechanisms of initiation of allergic response, genetic predisposition, biomarkers and identification of targets for therapy.
  • HEALTH.2010.2.4.5-2: Infection and dysbiosis as the triggers of the development of inflammatory processes in allergies and autoimmune diseases.

3. Optimising the delivery of healthcare to european citizens

3.2. Quality, efficiency and solidarity of healthcare systems includingtransitional health systems

  • HEALTH.2010.3.2-1: Financing systems' effect on quality of healthcare.
  • HEALTH.2010.3.2-2: Risk adjustment algorithms for better health insurance coverage.

3.4. International public health & health systems

  • HEALTH.2010.3.4-5: Assessment of migrants' health disease patterns and impact on health systems
  • HEALTH.2010.3.4-6: Impact and cost-effectiveness of existing major health programmes.
  • HEALTH.2010.3.4-7: Financing models for accessible health care

4. Other actions across the health theme

4.1. Coordination and support actions across the theme

  • HEALTH.2010.4.2-1: Off-patent medicines for children.
  • HEALTH.2010.4.2-2: International paediatric initiative.
  • HEALTH.2010.4.2-3: Adverse drug reaction research..
  • HEALTH.2010.4.2-4: International pluripotent stem cell registry.
  • HEALTH.2010.4.2-5: Methodology to evaluate and monitor health policy implementation and performance of EU funded interventions in developing countries.
  • HEALTH.2010.4.2-6: Impact of EU legislation on health research.
  • HEALTH.2010.4.2-7: International forum for European life sciences funders and performers.
  • HEALTH-2010.4.2-8: Coordination action in support of the implementation by participating States of a Joint Programming initiative for combating neurodegenerative diseases, in particular Alzheimer's disease.

European community funding

The Community provisional funding available for the call for proposals is:

  • 335,00 Million EUR (Global Budget)

All the important deadlines

  • 19 November 2009 - 11 years ago (Deadline for the presentation of proposals)

Further information about the call

Useful documents

  • FP7-HEALTH-2010-Single Stage (Legal base)

Organisations eligible to participate

Opened to the following bodies or institutes with legal status established in the covered areas:

  • Any legal organisation

Covered areas

Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:

  • European Union (EU)

Directorate-Generale responsible

Directorate-General for Research

Related calls for proposals

Related calls

Explore other programmes